S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
Log in
NASDAQ:ESPR

Esperion Therapeutics News Headlines

$25.93
+0.48 (+1.89 %)
(As of 01/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$25.19
Now: $25.93
$26.38
50-Day Range
$25.12
MA: $28.38
$31.36
52-Week Range
$23.90
Now: $25.93
$76.98
Volume929,329 shs
Average Volume915,025 shs
Market Capitalization$722.85 million
P/E RatioN/A
Dividend YieldN/A
Beta1.48

Headlines

Esperion Therapeutics (NASDAQ ESPR) News Headlines Today

Source:
SourceHeadline
Esperion Therapeutics (NASDAQ:ESPR) Stock Rating Lowered by Bank of AmericaEsperion Therapeutics (NASDAQ:ESPR) Stock Rating Lowered by Bank of America
marketbeat.com - January 15 at 8:34 AM
Esperion Therapeutics (NASDAQ:ESPR) Upgraded to "Outperform" by Credit Suisse GroupEsperion Therapeutics (NASDAQ:ESPR) Upgraded to "Outperform" by Credit Suisse Group
marketbeat.com - November 10 at 8:57 AM
Esperion Therapeutics (NASDAQ:ESPR) Downgraded by BidaskClubEsperion Therapeutics (NASDAQ:ESPR) Downgraded by BidaskClub
marketbeat.com - October 23 at 3:30 AM
Esperion Therapeutics (NASDAQ:ESPR) Receives New Coverage from Analysts at JPMorgan Chase & Co.Esperion Therapeutics (NASDAQ:ESPR) Receives New Coverage from Analysts at JPMorgan Chase & Co.
marketbeat.com - September 29 at 7:30 AM
Esperion Therapeutics (NASDAQ:ESPR) PT Lowered to $55.00Esperion Therapeutics (NASDAQ:ESPR) PT Lowered to $55.00
marketbeat.com - August 17 at 11:56 AM
Esperion Therapeutics (NASDAQ:ESPR) Cut to Neutral at Bank of AmericaEsperion Therapeutics (NASDAQ:ESPR) Cut to Neutral at Bank of America
americanbankingnews.com - January 15 at 4:02 PM
Esperion (ESPR) Reports Q4 Preliminary Results, Stock DownEsperion (ESPR) Reports Q4 Preliminary Results, Stock Down
finance.yahoo.com - January 14 at 7:54 PM
Esperion Therapeutics (NASDAQ:ESPR) Trading Down 11.1%Esperion Therapeutics (NASDAQ:ESPR) Trading Down 11.1%
americanbankingnews.com - January 13 at 11:18 PM
Notable Wednesday Option Activity: ESPR, CFR, DDNotable Wednesday Option Activity: ESPR, CFR, DD
nasdaq.com - January 13 at 6:18 PM
Why Esperion Therapeutics Stock Is Falling TodayWhy Esperion Therapeutics Stock Is Falling Today
finance.yahoo.com - January 13 at 6:18 PM
Investors Purchase Large Volume of Call Options on Esperion Therapeutics (NASDAQ:ESPR)Investors Purchase Large Volume of Call Options on Esperion Therapeutics (NASDAQ:ESPR)
americanbankingnews.com - January 13 at 12:12 PM
ESPERION Reports Preliminary Fourth Quarter 2020 Financial Results and Further Commits to Unmet Patient Needs with Oral PCSK9 Inhibitor ProgramESPERION Reports Preliminary Fourth Quarter 2020 Financial Results and Further Commits to Unmet Patient Needs with Oral PCSK9 Inhibitor Program
finance.yahoo.com - January 13 at 8:12 AM
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Given Consensus Rating of "Buy" by BrokeragesEsperion Therapeutics, Inc. (NASDAQ:ESPR) Given Consensus Rating of "Buy" by Brokerages
americanbankingnews.com - January 6 at 10:48 AM
Esperion Therapeutics (NASDAQ:ESPR) Shares Up 6.6%Esperion Therapeutics (NASDAQ:ESPR) Shares Up 6.6%
americanbankingnews.com - January 4 at 9:14 PM
Esperion to Present at the 39th Annual J.P. Morgan Healthcare ConferenceEsperion to Present at the 39th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - December 21 at 1:26 PM
Need To Know: Esperion Therapeutics, Inc. (NASDAQ:ESPR) Insiders Have Been Buying SharesNeed To Know: Esperion Therapeutics, Inc. (NASDAQ:ESPR) Insiders Have Been Buying Shares
finance.yahoo.com - December 19 at 1:58 PM
Is ESPR A Good Stock To Buy Now?Is ESPR A Good Stock To Buy Now?
finance.yahoo.com - December 16 at 6:03 PM
Why BioLine, Esperion And More Are Moving TodayWhy BioLine, Esperion And More Are Moving Today
benzinga.com - December 16 at 1:03 PM
First-in-class cholesterol-lowering treatment NILEMDO® * (bempedoic acid) tablet and its combination with ezetimibe NUSTENDI® * (bempedoic acid and ezetimibe) tablet approved in SwitzerlandFirst-in-class cholesterol-lowering treatment NILEMDO® * (bempedoic acid) tablet and its combination with ezetimibe NUSTENDI® * (bempedoic acid and ezetimibe) tablet approved in Switzerland
finance.yahoo.com - December 16 at 8:02 AM
ESPERION Appoints Sheldon Koenig as Chief Operating OfficerESPERION Appoints Sheldon Koenig as Chief Operating Officer
finance.yahoo.com - December 15 at 12:00 PM
Why Is Esperion Therapeutics (ESPR) Up 17.5% Since Last Earnings Report?Why Is Esperion Therapeutics (ESPR) Up 17.5% Since Last Earnings Report?
finance.yahoo.com - December 2 at 4:04 PM
Should Value Investors Buy Esperion Therapeutics (ESPR) Stock?Should Value Investors Buy Esperion Therapeutics (ESPR) Stock?
finance.yahoo.com - December 2 at 4:04 PM
NEXLETOL® (bempedoic acid) Tablets Highlighted at AHA 2020 with Presentations of Analyses Demonstrating Significant Low-Density Lipoprotein Cholesterol (LDL-C) Lowering vs. Placebo in Phase 3 Study SubgroupsNEXLETOL® (bempedoic acid) Tablets Highlighted at AHA 2020 with Presentations of Analyses Demonstrating Significant Low-Density Lipoprotein Cholesterol (LDL-C) Lowering vs. Placebo in Phase 3 Study Subgroups
finance.yahoo.com - November 13 at 12:09 PM
Esperion Announces Pricing of Offering of $250.0 Million of Convertible Senior Subordinated NotesEsperion Announces Pricing of Offering of $250.0 Million of Convertible Senior Subordinated Notes
finance.yahoo.com - November 12 at 8:07 AM
Esperion Announces Private Offering of $200.0 Million of Convertible Senior Subordinated NotesEsperion Announces Private Offering of $200.0 Million of Convertible Senior Subordinated Notes
finance.yahoo.com - November 10 at 6:13 PM
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Just Reported And Analysts Have Been Cutting Their EstimatesEsperion Therapeutics, Inc. (NASDAQ:ESPR) Just Reported And Analysts Have Been Cutting Their Estimates
nasdaq.com - November 4 at 9:24 AM
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Analysts Are Cutting Their Estimates: Heres What You Need To KnowEsperion Therapeutics, Inc. (NASDAQ:ESPR) Analysts Are Cutting Their Estimates: Here's What You Need To Know
finance.yahoo.com - November 4 at 9:24 AM
Esperion (ESPR) Q3 Earnings Top, Coronavirus Woes LingerEsperion (ESPR) Q3 Earnings Top, Coronavirus Woes Linger
finance.yahoo.com - November 3 at 1:40 PM
Esperion Therapeutics, Inc. to Host Earnings CallEsperion Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - November 2 at 2:52 PM
Esperion Therapeutics Q3 2020 Earnings PreviewEsperion Therapeutics Q3 2020 Earnings Preview
seekingalpha.com - November 1 at 5:59 PM
Esperion to Participate in Three Upcoming Virtual Investor ConferencesEsperion to Participate in Three Upcoming Virtual Investor Conferences
finance.yahoo.com - October 27 at 12:38 PM
Earnings Preview: Esperion Therapeutics (ESPR) Q3 Earnings Expected to DeclineEarnings Preview: Esperion Therapeutics (ESPR) Q3 Earnings Expected to Decline
finance.yahoo.com - October 26 at 2:31 PM
Esperion to Report Third Quarter 2020 Financial Results November 2, 2020Esperion to Report Third Quarter 2020 Financial Results November 2, 2020
finance.yahoo.com - October 19 at 10:41 AM
Esperion Therapeutics, Inc.s (NASDAQ:ESPR) Intrinsic Value Is Potentially 33% Above Its Share PriceEsperion Therapeutics, Inc.'s (NASDAQ:ESPR) Intrinsic Value Is Potentially 33% Above Its Share Price
uk.finance.yahoo.com - September 28 at 7:31 PM
Esperion Therapeutics, Inc.'s (NASDAQ:ESPR) Intrinsic Value Is Potentially 33% Above Its Share PriceEsperion Therapeutics, Inc.'s (NASDAQ:ESPR) Intrinsic Value Is Potentially 33% Above Its Share Price
finance.yahoo.com - September 22 at 1:47 PM
Esperion to Participate in Two Upcoming Virtual Investor ConferencesEsperion to Participate in Two Upcoming Virtual Investor Conferences
finance.yahoo.com - September 2 at 2:10 PM
Esperion Announces Two Data Presentations of NEXLETOL(R) (bempedoic acid) Tablet at the ESC Congress 2020Esperion Announces Two Data Presentations of NEXLETOL(R) (bempedoic acid) Tablet at the ESC Congress 2020
marketwatch.com - August 26 at 12:05 PM
Esperion (ESPR) Q2 Earnings Top, Drug Sales Hurt by CoronavirusEsperion (ESPR) Q2 Earnings Top, Drug Sales Hurt by Coronavirus
finance.yahoo.com - August 11 at 5:15 PM
Esperion Therapeutics, Inc. (ESPR) CEO Tim Mayleben on Q2 2020 Results - Earnings Call TranscriptEsperion Therapeutics, Inc. (ESPR) CEO Tim Mayleben on Q2 2020 Results - Earnings Call Transcript
seekingalpha.com - August 11 at 4:24 AM
Esperion Therapeutics Inc (ESPR) Q2 2020 Earnings Call TranscriptEsperion Therapeutics Inc (ESPR) Q2 2020 Earnings Call Transcript
finance.yahoo.com - August 11 at 4:24 AM
Esperion Reports Second Quarter 2020 Financial Results and Provides Company UpdateEsperion Reports Second Quarter 2020 Financial Results and Provides Company Update
finance.yahoo.com - August 10 at 6:23 PM
Esperion Therapeutics (ESPR) Beats Q2 Earnings EstimatesEsperion Therapeutics (ESPR) Beats Q2 Earnings Estimates
finance.yahoo.com - August 10 at 6:23 PM
Esperion Therapeutics Q2 2020 Earnings PreviewEsperion Therapeutics Q2 2020 Earnings Preview
seekingalpha.com - August 9 at 7:42 PM
Were Hedge Funds Right About Betting On Esperion Therapeutics (ESPR)?Were Hedge Funds Right About Betting On Esperion Therapeutics (ESPR)?
finance.yahoo.com - August 7 at 10:46 AM
Esperion Therapeutics(NASDAQ:ESPR) Share Price Is Down 42% Over The Past Five Years.Esperion Therapeutics'(NASDAQ:ESPR) Share Price Is Down 42% Over The Past Five Years.
finance.yahoo.com - August 6 at 2:01 PM
Esperion Therapeutics'(NASDAQ:ESPR) Share Price Is Down 42% Over The Past Five Years.Esperion Therapeutics'(NASDAQ:ESPR) Share Price Is Down 42% Over The Past Five Years.
finance.yahoo.com - August 6 at 2:01 PM
Esperion to Report Second Quarter 2020 Financial Results August 10, 2020Esperion to Report Second Quarter 2020 Financial Results August 10, 2020
finance.yahoo.com - August 3 at 8:44 AM
ESPR Aug 2020 40.000 callESPR Aug 2020 40.000 call
uk.finance.yahoo.com - July 26 at 5:42 PM
Esperion Therapeutics Becomes OversoldEsperion Therapeutics Becomes Oversold
www.nasdaq.com - July 24 at 6:31 PM
Esperion Therapeutics Scores Relative Strength Rating Upgrade; Hits Key ThresholdEsperion Therapeutics Scores Relative Strength Rating Upgrade; Hits Key Threshold
finance.yahoo.com - July 16 at 7:26 PM
Esperion Announces Publication in the Journal of the American Medical Association Cardiology of Pooled Efficacy Analysis from the Phase 3 LDL-C Lowering Clinical Development Program of NEXLETOL® (bempedoic acid) TabletsEsperion Announces Publication in the Journal of the American Medical Association Cardiology of Pooled Efficacy Analysis from the Phase 3 LDL-C Lowering Clinical Development Program of NEXLETOL® (bempedoic acid) Tablets
finance.yahoo.com - July 1 at 1:45 PM
Esperion Therapeutics: An Easy Double, Maybe A Lot MoreEsperion Therapeutics: An Easy Double, Maybe A Lot More
seekingalpha.com - June 26 at 4:26 AM
Esperion Therapeutics, Inc. (ESPR): Hedge Funds Are Getting BullishEsperion Therapeutics, Inc. (ESPR): Hedge Funds Are Getting Bullish
finance.yahoo.com - June 23 at 1:41 PM
Esperion Announces Pooled Analysis from Phase 3 LDL-C Lowering Clinical Development Program of NEXLETOL™ (Bempedoic Acid) Tablets Presented at the American Diabetes Association 80th Scientific SessionsEsperion Announces Pooled Analysis from Phase 3 LDL-C Lowering Clinical Development Program of NEXLETOL™ (Bempedoic Acid) Tablets Presented at the American Diabetes Association 80th Scientific Sessions
finance.yahoo.com - June 14 at 10:48 AM
Edited Transcript of ESPR earnings conference call or presentation 6-May-20 8:30pm GMTEdited Transcript of ESPR earnings conference call or presentation 6-May-20 8:30pm GMT
finance.yahoo.com - June 12 at 3:08 PM
This page was last updated on 1/23/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.